ストックスクリーナーアプリを入手
18.18
1.45%
0.26
アフターアワーズ：
18.24
0.06
+0.33%
Alumis Inc (ALMS) 最新ニュース
Why Alumis Inc. stock could outperform in 20252025 Volatility Report & High Accuracy Swing Trade Signals - ulpravda.ru
Can Alumis Inc. stock maintain growth trajectoryJuly 2025 Movers & Verified Momentum Stock Watchlist - ulpravda.ru
How Alumis Inc. stock reacts to job market dataWatch List & Risk Managed Trade Strategies - ulpravda.ru
Why Alumis Inc. stock is favored by top institutionsQuarterly Trade Report & Free Weekly Watchlist of Top Performers - ulpravda.ru
Will Alumis Inc. stock deliver long term returnsChart Signals & Community Consensus Trade Alerts - ulpravda.ru
Can Alumis Inc. stock hit record highs againJuly 2025 Levels & Real-Time Market Sentiment Alerts - ulpravda.ru
Will Alumis Inc. stock beat EPS estimatesTrade Ideas & Free Real-Time Volume Trigger Notifications - ulpravda.ru
What's Going On With Alumis Stock Thursday? - Benzinga
Alumis Prices Upsized $300 Million Public Offering of Common Shares - MarketScreener
Assessing Alumis (ALMS) Valuation After Positive Phase 3 Psoriasis Data And Strong Share Price Momentum - Yahoo Finance
Alumis (ALMS) Is Up 83.6% After Phase 3 Psoriasis Win And NDA PlanHas The Bull Case Changed? - simplywall.st
Why a California biotech is selling 17,650,000 new shares to the public - Stock Titan
Alumis prices upsized public offering of common stock at $17 per share - Investing.com
Alumis Inc. Announces Pricing of Upsized Public Offering of 17.65 Million Shares at $17.00 Each - Quiver Quantitative
Alumis Announces Pricing of Upsized Public Offering of Common Stock - The Manila Times
Alumis announces pricing of upsized public offering of common stock - MarketScreener
Alumis Announces Pricing of Upsized Public Offering of Common Stock - GlobeNewswire Inc.
ALMS Surges as Envudeucitinib Meets Goals in Plaque Psoriasis Studies - Yahoo Finance
Should You Chase the Rally in Alumis Stock Today? - Barchart.com
Alumis Up On Phase 3 Envudeucitinib Success: Oral Psoriasis Therapy Shows Promise (ALMS) - Seeking Alpha
Biopharma firm Alumis extends gains after commencing $175 mln stock offering - TradingView — Track All Markets
Guggenheim raises Alumis stock price target to $32 on positive trial data - Investing.com Nigeria
Alumis Stock Hits Record High As Wall Street Cheers Phase 3 Psoriasis ‘Win’ — Analysts See Best-In-Class Potential - Stocktwits
Why Alumis Stock Spiked Almost 100% Yesterday - TIKR.com
Alumis stock hits record high as Wall Street cheers phase 3 psoriasis 'win' — analysts see best-in-class potential - MSN
Should You Jump Into the Alumis Stock Rally Now? - Bitget
Alumis (ALMS) Sees Analyst Rating Boost with New Price Target | - GuruFocus
Sandisk, Alumis, Micron Technology, Ventyx Biosciences, And Western Digital: Why These 5 Stocks Are On Investors' Radars Today - Benzinga
Alumis Inc. (ALMS) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Assessing Alumis (ALMS) Valuation After Positive Envudeucitinib Phase 3 Trial Success - simplywall.st
Alumis plans $175 million common stock offering By Investing.com - Investing.com Nigeria
Stock Market Today, Jan. 6: Alumis Shares Surge on Positive Phase 3 Psoriasis Data for Envudeucitinib - Yahoo Finance
Alumis’ TYK2 envu in view as standout in psoriasis phase III - BioWorld MedTech
Alumis stock nearly doubles on 'truly remarkable' drug trial, plan to seek FDA approval - The Business Journals
Alumis Looks To Come From Behind In TYK2 Race - Citeline News & Insights
Why This J&J Rival Just Catapulted More Than 95% - Investor's Business Daily
Alumis Announces Proposed Public Offering of Common Stock - The Manila Times
Biotech Alumis plans $175M stock sale in new public offering - Stock Titan
Alumis (ALMS) Sees Analyst Rating Boost with New Price Target | ALMS Stock News - GuruFocus
Alumis Inc.: Is It Too Late To Buy? - StocksToTrade
Oppenheimer raises Alumis stock price target to $50 on positive trial results - Investing.com UK
Dow Jumps Over 400 Points; US Services Activity Falls In December - Benzinga
Alumis posts late-stage trial successes for TYK2 inhibitor in plaque psoriasis - FirstWord
Alumis Inc. Stock (ALMS) Opinions on Phase 3 Trial Results - Quiver Quantitative
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
Alumis soars as TYK2 drug hits mark in psoriasis trials - BioPharma Dive
Alumis (NASDAQ:ALMS) Sets New 12-Month HighWhat's Next? - MarketBeat
Alumis Skin Medication Demonstrates Significant Advantages in Advanced Trials, Shares Surge - Bitget
Alumis’ TYK2 drug succeeds in key psoriasis studies, will seek FDA approval - Endpoints News
Baird raises Alumis stock price target to $35 on strong psoriasis trial data - Investing.com Nigeria
Alumis Shares Jump as Envudeucitinib Hits Phase III Endpoints in Psoriasis, NDA Planned for 2026 - MarketBeat
Alumis Stock Hits Record High on Psoriasis Drug Trial Results - Schaeffer's Investment Research
Alumis price target raised to $39 from $17 at Wells Fargo - TipRanks
Alumis Skin Drug Shows Clear Benefits In Late Trials, Stock Soars - Benzinga
0.80%
4.56%
大文字化:
|
ボリューム (24 時間):